DXC016 / Hangzhou DAC Biotech - LARVOL DELTA

DXC016, a novel cMET-targeting dual payload antibody-drug conjugate, demonstrates potent antitumor activity and favorable PK for potential subcutaneous use (AACR 2026) - "Across multiple cMET-expressing tumor models, including SNU-5 (gastric), EBC-1 (NSCLC), HCT116 (colorectal), SW1990 (pancreatic), and an osimertinib-resistant NSCLC model, DXC016 demonstrated potent in vitro and in vivo antitumor activity, archived tumor regression at doses below 1.5 mg/kg and outperformed DXd and MMAE-based benchmark ADCs, highlighting the superior efficacy enabled by the dual-payload design. In preliminary safety studies in rats and cynomolgus monkeys with once-weekly dosing for three administrations, DXC016 was well tolerated up to 80 mg/kg in rats and 50 mg/kg in monkeys, with no treatment-related mortality observed, indicating a favorable early safety profile. Collectively, the strong antitumor efficacy, improved subcutaneous absorption profile with DXE001, and encouraging preliminary safety characteristics support DXC016 as a promising clinical development candidate of next-generation cMET-targeting ADC."

ADC • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor